Columbia University Medical Center, New York, New York.
J Clin Sleep Med. 2019 Mar 15;15(3):515-517. doi: 10.5664/jcsm.7690.
A 12-year-old girl with normal neurodevelopment and narcolepsy type 1 presented with unexpected central apneas in response to sodium oxybate (SO). The patient underwent overnight polysomnography on SO (2.75 + 2.5 grams) which showed an apnea-hypopnea index of 4.3 events/h, and all the events were central apneas. A majority of central apneas clustered at about 1.5 hours after the first dose of SO. Remarkably, after a second dose of SO that was 0.25 grams smaller, she did not exhibit clusters of central sleep apneas. However, she did experience similar but milder breathing abnormalities that did not meet criteria to be scored as central apneas or hypopneas. Based on this observation, there may be an association between SO treatment and the development of central apnea. Further polysomnographic research on pediatric patients taking SO would help determine if there is a significant association between SO treatment and the development of central apnea in the pediatric population.
一位 12 岁的女孩，神经发育正常，患有 1 型发作性睡病，在服用羟丁酸钠（SO）后出现意外中枢性呼吸暂停。患者在服用 SO（2.75+2.5 克）后进行了一夜的多导睡眠图检查，结果显示呼吸暂停低通气指数为 4.3 次/小时，所有事件均为中枢性呼吸暂停。大多数中枢性呼吸暂停集中在服用 SO 后的大约 1.5 小时。值得注意的是，在服用第二剂 SO 时，剂量减少了 0.25 克，她没有出现中枢性睡眠呼吸暂停的集群。然而，她确实经历了类似但更轻微的呼吸异常，但不符合被评为中枢性呼吸暂停或呼吸不足的标准。基于这一观察结果，SO 治疗与中枢性呼吸暂停的发展之间可能存在关联。进一步对接受 SO 治疗的儿科患者进行多导睡眠图研究，有助于确定 SO 治疗与儿科人群中中枢性呼吸暂停的发展之间是否存在显著关联。
